《原发纵隔大B细胞淋巴瘤诊治中国专家共识(2024年版)》解读

Interpretation of Chinese expert consensus on the diagnosis and management of primary mediastinal large B-cell lymphoma(2024)

原发纵隔大B细胞淋巴瘤(primary mediastinal large B-cell lymphoma,PMBL)是一种原发于纵隔的侵袭性大B细胞淋巴瘤,具有独特的临床、病理及分子学特征。近年来,对PMBL发病机制的认识、诊断及治疗均有不同程度的进展,特别是新药治疗领域取得了较大突破。为提高我国临床医师对PMBL的诊断及治疗水平,中华医学会血液病学分会淋巴细胞疾病学组和中国临床肿瘤学会抗淋巴瘤联盟组织相关专家,制订了《原发纵隔大B细胞淋巴瘤诊治中国专家共识(2024年版)》。为更好地指导临床实践,文章拟对该共识的诊断及个体化分层治疗部分进行解读。

Primary mediastinal large B-cell lymphoma(PMBL)is an aggressive B-cell lymphoma that is thought to arise from thymic(medullary)B cells and has unique clinicopathologic and molecular features.In recent years,the understanding of the pathogenesis and treatment of PMBL has been updated to varying degrees,particularly in the area of new drug therapy.In order to improve the diagnosis and treatment of PMBL in China,the Lymphocyte Disease Group of the Chinese Medical Association(CMA)and the Anti-Lymphoma Alliance of the Chinese Society of Clinical Oncology commissioned a group of experts to formulate the"Chinese expert consensus on the diagnosis and management of primary mediastinal large B-cell lymphoma(2024)".To better guide clinical practice,this paper intends to interpret the diagnostic part and individualized stratified treatment of this consensus.